Novartis to present positive results from the pivotal Phase III trial of ianalumab in ITP patients at ASH Annual Meeting & Exposition. Scemblix data shows new evidence for CML care. 96-week pelabresib Phase III data represents longest follow-up in myelofibrosis patients. Kisqali data adds to benefits for breast cancer patients. Novartis emphasizes commitment to transformative care and patient impact through innovation in hematology and oncology. Novartis leads in breast cancer research with comprehensive portfolio. Forward-looking statements caution on risks and uncertainties in the industry. Visit Novartis website for more information.

Read more at GlobeNewswire: Novartis data underscore pioneering scientific innovation